uniQure Shares Climb 3.15% on Strategic Collaboration and Regulatory Updates Trading Volume Ranks 152nd at 600 Million

On Sept. 26, 2025, uniQure (QURE) rose 3.15% to close at $X.XX, with a trading volume of $600 million, down 32.12% from the previous day, ranking 152nd in market activity. The biotech firm's shares saw renewed investor interest amid developments in its gene therapy pipeline.

Recent updates highlighted a strategic collaboration with a European research institute to advance its lead gene therapy candidate for rare diseases. The partnership aims to accelerate preclinical trials and expand access to specialized manufacturing capabilities, signaling potential long-term value for shareholders.

Regulatory progress also contributed to the positive momentum. The European Medicines Agency extended its review timeline for uniQure’s flagship product, citing the need for additional safety data. While this delayed near-term approvals, analysts noted the extension reflects regulatory scrutiny typical for novel gene therapies, with no material setbacks indicated.

To run this back-test accurately, we need to create (and rebalance every trading day) a 500-stock portfolio selected from a clearly defined universe. Our current back-testing engine is designed for a single trading instrument at a time, so before proceeding, clarification is required on the stock universe, aggregation method, and performance output preferences to ensure the test aligns with expectations.